calcium only or the geniVidaTM bone blend (GBB)	placebo	bone mineral density (BMD)	1359	1481	There was also a significant difference (p < 0.05) in BMD between the groups at Ward's triangle in favor of the GBB group.
calcium only or the geniVidaTM bone blend (GBB)	placebo	estradiol (E2)	-1	-1	<td align="left">(pg/mL)</td><td align="char" char="(">10.2 (2.1)</td><td align="char" char="(">11.5 (3.9)</td><td align="left"><italic>p</italic>&nbsp;=&nbsp;0.044</td><td align="char" char="(">10.4 (3.3)</td><td align="char" char="(">10.7 (2.3)</td><td align="left">ns</td><td align="left">ns</td><td align="left">ns</td>
calcium only or the geniVidaTM bone blend (GBB)	placebo	bone mineral density (BMD)	-1	-1	At the 6-month time point, subjects supplemented with the GBB (n = 30) maintained femoral neck BMD, whereas in the placebo group (n = 28), BMD significantly decreased (p = 0.007, Fig. 2a)
calcium only or the geniVidaTM bone blend (GBB)	baseline	Endometrial Thickness	25346	25454	However, ET significantly decreased in the GBB group between screening and study end (2.3â€“1.8 mm, p = 0.007)
placebo	baseline	bone mineral density (BMD) At the 6-month time point	-1	-1	At the 6-month time point, subjects supplemented with the GBB (n = 30) maintained femoral neck BMD, whereas in the placebo group (n = 28), BMD significantly decreased (p = 0.007, Fig. 2a), resulting in a 1.3% difference between groups (p < 0.05).
